Clinical Report: BP Targets Across CKM Stages

Overview

Intensive blood pressure control to less than 130/80 mmHg may be associated with a reduction in major adverse cardiovascular events across stages II to IV of cardiovascular-kidney-metabolic syndrome, based on a post hoc analysis of a cluster randomized clinical trial.

Background

Effective management of blood pressure is crucial in patients with cardiovascular-kidney-metabolic syndrome, as it can significantly impact cardiovascular outcomes. Recent guidelines advocate for tighter blood pressure targets, emphasizing the need for intensive management strategies. Understanding the implications of these targets across different stages of the syndrome can guide clinical practice and improve patient outcomes.

Data Highlights

Key Findings

• Intensive BP control (<130/80 mmHg) reduced major adverse cardiovascular events across CKM stages.
• Stroke contributed the largest absolute risk reduction within the composite outcome.
• All-cause mortality was reduced in stages II and III but not in stage IV.
• Hypotension occurred more frequently in the intensive treatment group.
• Absolute risk increases in total adverse events ranged from 0.97% to 1.41%, indicating a need for careful patient selection.

Clinical Implications

Clinicians should consider implementing intensive blood pressure management strategies in patients with cardiovascular-kidney-metabolic syndrome to reduce the risk of major cardiovascular events. However, careful monitoring for hypotension and other adverse effects, such as injurious falls and syncope, is essential, particularly in higher-risk populations.

Conclusion

The findings support the efficacy of intensive blood pressure control in reducing cardiovascular risks across various stages of cardiovascular-kidney-metabolic syndrome, while also highlighting the importance of tailored management approaches in clinical practice. Limitations of the study should be considered when applying these findings.

References

1. American College of Cardiology, New High Blood Pressure Guideline Emphasizes Prevention, Early Treatment to Reduce CVD Risk, 2025 -- New High Blood Pressure Guideline Emphasizes Prevention, Early Treatment to Reduce CVD Risk
2. American College of Cardiology, Intensive BP Control Provides Net Benefit Between Fewer CV and More Adverse Events, 2025 -- Intensive BP Control Provides Net Benefit Between Fewer CV and More Adverse Events
3. The Journal of Clinical Endocrinology & Metabolism — Metabolic Bone Disease Linked to Cystinosis in Patients of Varying Ages and CKD Stages 1 to 5D/T
4. Archives of Toxicology — Inhibition of Rabbit Muscle Creatine Kinase Activity In Vitro Through Alkylation of Surface Methionine Residues
5. Blood Cancer Journal — Negative Prognosis for Chronic Myeloid Leukemia Patients Exhibiting Splenomegaly and Reduced In Vivo Kinase Activity on Imatinib
6. Archives of Toxicology — Screening a Comprehensive Kinase Inhibitor Library via Live Cell Imaging in hiPSC-ICAM1-eGFP Reporter Models Reveals Vulnerabilities in TNFα Pathway Regulation
7. 2025 High Blood Pressure Guideline - Professional Heart Daily | American Heart Association
8. New High Blood Pressure Guideline Emphasizes Prevention, Early Treatment to Reduce CVD Risk - American College of Cardiology
9. Intensive BP Control Provides Net Benefit Between Fewer CV and More Adverse Events - American College of Cardiology